MA33212B1 - Procedes d'amelioration de pharmacocinetique - Google Patents

Procedes d'amelioration de pharmacocinetique

Info

Publication number
MA33212B1
MA33212B1 MA34273A MA34273A MA33212B1 MA 33212 B1 MA33212 B1 MA 33212B1 MA 34273 A MA34273 A MA 34273A MA 34273 A MA34273 A MA 34273A MA 33212 B1 MA33212 B1 MA 33212B1
Authority
MA
Morocco
Prior art keywords
methods
improving pharmacokinetics
pharmacokinetics
improving
cytochrome
Prior art date
Application number
MA34273A
Other languages
Arabic (ar)
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33212B1 publication Critical patent/MA33212B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'objectif de la présente invention est d'élever le taux sanguin d'un composé de formule I par co-administration avec un inhibiteur du cytochrome P450.
MA34273A 2009-04-25 2010-04-22 Procedes d'amelioration de pharmacocinetique MA33212B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25
PCT/EP2010/055317 WO2010122087A1 (fr) 2009-04-25 2010-04-22 Procédés d'amélioration de pharmacocinétique

Publications (1)

Publication Number Publication Date
MA33212B1 true MA33212B1 (fr) 2012-04-02

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34273A MA33212B1 (fr) 2009-04-25 2010-04-22 Procedes d'amelioration de pharmacocinetique

Country Status (36)

Country Link
US (4) US20100272682A1 (fr)
EP (1) EP2421527B1 (fr)
JP (1) JP5523552B2 (fr)
KR (1) KR101471238B1 (fr)
CN (2) CN102413827A (fr)
AR (1) AR076388A1 (fr)
AU (1) AU2010240893B2 (fr)
BR (1) BRPI1015147B1 (fr)
CA (1) CA2758644C (fr)
CL (1) CL2011002643A1 (fr)
CO (1) CO6440593A2 (fr)
CR (1) CR20110551A (fr)
DK (1) DK2421527T3 (fr)
EC (1) ECSP11011420A (fr)
ES (1) ES2683736T3 (fr)
HK (1) HK1215858A1 (fr)
HR (1) HRP20181306T1 (fr)
HU (1) HUE040182T2 (fr)
IL (1) IL215620A (fr)
LT (1) LT2421527T (fr)
MA (1) MA33212B1 (fr)
MX (2) MX2011011105A (fr)
MY (1) MY169734A (fr)
NZ (1) NZ595917A (fr)
PE (1) PE20120638A1 (fr)
PL (1) PL2421527T3 (fr)
PT (1) PT2421527T (fr)
RS (1) RS57501B1 (fr)
RU (1) RU2591830C2 (fr)
SG (1) SG175328A1 (fr)
SI (1) SI2421527T1 (fr)
TR (1) TR201809600T4 (fr)
TW (1) TWI468160B (fr)
UA (1) UA103801C2 (fr)
WO (1) WO2010122087A1 (fr)
ZA (1) ZA201107421B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (fr) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Composition pharmaceutique pour le traitement d'infections par VHC
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (fr) 2011-10-21 2015-05-05 Abbvie Inc. Methodes de traitement du vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2863002A1 (fr) 2012-01-11 2013-07-18 Abbvie Inc. Procedes de preparation d'inhibiteurs de protease du vhc
WO2014004674A2 (fr) * 2012-06-27 2014-01-03 Abbvie Inc. Méthodes de traitement du vhc
EP2903988A1 (fr) 2012-10-08 2015-08-12 AbbVie Inc. Composés utiles dans la fabrication d'inhibiteurs de protéase du vhc
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102686313B1 (ko) * 2014-05-01 2024-07-17 아이거 바이오파마슈티컬스 인코포레이티드 델타 간염 바이러스 감염의 치료
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10835496B2 (en) 2015-04-21 2020-11-17 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69305093T2 (de) 1992-12-29 1997-04-17 Abbott Lab Inhibitoren der retroviralen protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
WO2002008187A1 (fr) * 2000-07-21 2002-01-31 Schering Corporation Nouveaux peptides utilises comme inhibiteurs de la serine protease ns3 du virus de l'hepatite c
US20040152625A1 (en) 2002-12-16 2004-08-05 Boehringer Ingelheim International Gmbh Method for improving the pharmacokinetics of an NNRTI
EP1677827B1 (fr) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Inhibiteurs combin s destin s au traitement du vhc
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
DK2421527T3 (en) 2018-08-13
ES2683736T3 (es) 2018-09-27
TW201041582A (en) 2010-12-01
MY169734A (en) 2019-05-14
EP2421527B1 (fr) 2018-06-13
WO2010122087A1 (fr) 2010-10-28
TR201809600T4 (tr) 2018-07-23
RU2591830C2 (ru) 2016-07-20
BRPI1015147A2 (pt) 2018-01-30
AU2010240893A1 (en) 2011-11-03
CL2011002643A1 (es) 2012-05-25
PT2421527T (pt) 2018-08-02
RU2011142651A (ru) 2013-05-27
TWI468160B (zh) 2015-01-11
SG175328A1 (en) 2011-11-28
UA103801C2 (ru) 2013-11-25
SI2421527T1 (sl) 2018-09-28
US10918626B2 (en) 2021-02-16
LT2421527T (lt) 2018-09-10
US20180318267A1 (en) 2018-11-08
CA2758644C (fr) 2018-01-09
AU2010240893B2 (en) 2015-02-05
HK1215858A1 (zh) 2016-09-23
ECSP11011420A (es) 2011-11-30
CN105233249A (zh) 2016-01-13
HRP20181306T1 (hr) 2018-10-19
AR076388A1 (es) 2011-06-08
RS57501B1 (sr) 2018-10-31
ZA201107421B (en) 2022-11-30
CA2758644A1 (fr) 2010-10-28
CN102413827A (zh) 2012-04-11
US20200230112A1 (en) 2020-07-23
IL215620A0 (en) 2012-01-31
EP2421527A1 (fr) 2012-02-29
MX351185B (es) 2017-10-04
BRPI1015147B1 (pt) 2022-03-08
CO6440593A2 (es) 2012-05-15
PL2421527T3 (pl) 2018-10-31
JP2012524753A (ja) 2012-10-18
KR20120014170A (ko) 2012-02-16
KR101471238B1 (ko) 2014-12-12
JP5523552B2 (ja) 2014-06-18
MX2011011105A (es) 2011-11-18
US20170119739A1 (en) 2017-05-04
US20100272682A1 (en) 2010-10-28
NZ595917A (en) 2014-02-28
PE20120638A1 (es) 2012-05-26
HUE040182T2 (hu) 2019-02-28
IL215620A (en) 2015-10-29
CR20110551A (es) 2011-12-13

Similar Documents

Publication Publication Date Title
MY169734A (en) Methods for improving pharmacokinetics
TN2011000400A1 (en) Inhibitors of beta-secretase
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
UA107652C2 (en) Carbazole compounds and therapeutic uses of the compounds
MA32231B1 (fr) Composés organiques
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
CO6351737A2 (es) Amidofenoxiindazoles utiles como inhibidores de c-met
MX342377B (es) Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
UA108738C2 (uk) Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
MY172860A (en) Dimethyl-benzoic acid compounds
MX2012001617A (es) Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1.
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
NZ712660A (en) Dicarboxylic acid compound
SG11201808171PA (en) Griseofulvin compound
RU2012146325A (ru) Терапевтическое средство или профилактическое средство для лечения фибромиалгии